Clinical Trials · NCT07037459
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Amgen
- Enrollment
- 5,056
- Start date
- Jun 2025
- Locations
- 628 sites, 34 countries
- Primary endpoint
- Time to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF Events